Swiss pharma giant Roche Holding AG (RHHBY) posted strong growth in the second quarter and first half of 2024 that propelled the company to raise its annual earnings guidance.Second-quarter revenues increased 7% to CHF 15.4 billion. Sales were up 9% at constant exchange rates (CER) as the decline in COVID-19-related product sales no longer affected the overall top-line growth.The company reports under two divisions — Pharmaceuticals and Diagnostics. All growth rates mentioned below are on a year-over-year b ...